{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:22:13Z","timestamp":1790410933371,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,3,27]],"date-time":"2013-03-27T00:00:00Z","timestamp":1364342400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Despite the existence of effective treatment, tuberculosis is still a global public health issue. The World Health Organization recommends a six-month four-drug regimen in fixed-dose combination formulation to treat drug sensitive tuberculosis, and long course regimens with several second-line drugs to treat multi-drug resistant tuberculosis. To achieve the projected tuberculosis elimination goal by 2050, it will be essential to ensure a non-interrupted supply of quality-assured tuberculosis drugs. However, quality and affordable tuberculosis drug supply is still a significant challenge for National Tuberculosis Programs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>Quality drug production requires a combination of complex steps. The first challenge is to guarantee the quality of tuberculosis active pharmaceutical ingredients, then ensure an adequate manufacturing process, according to international standards, to guarantee final product\u00b4s safety, efficacy and quality. Good practices for storage, transport, distribution and quality control procedures must follow. In contrast to other high-burden countries, Brazil produces tuberculosis drugs through a strong network of public sector drug manufacturers regulated by a World Health Organization-certified national sanitary authority. The installed capacity for production surpasses the 71,000 needed treatments in the country. However, in order to be prepared to act as a global supplier, important bottlenecks are to be overcome. This article presents an in-depth analysis of the current status of production of tuberculosis drugs in Brazil and the bottlenecks and opportunities for the country to sustain national demand and play a role as a potential global supplier. Raw material and drug production, quality control, international certification and pre-qualification, political commitment and regulatory aspects are discussed, as well recommendations for tackling these bottlenecks. This discussion becomes more important as new drugs and regimens to treat tuberculosis are expected in a close future.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>International manufacturers of raw material for tuberculosis treatment should undergo certification and pre-qualify their active pharmaceutical ingredients as a first step to ensure quality of tuberculosis drugs. At the country level, Brazilian public manufacturers should apply for international certification and tuberculosis drugs should be pre-qualified by international organisms. Finally, only with political commitment and large-scale production will Brazilian public sector manufacturers be able to partially supply the global market.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2458-13-279","type":"journal-article","created":{"date-parts":[[2013,3,27]],"date-time":"2013-03-27T21:21:41Z","timestamp":1364419301000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Can Brazil play a more important role in global tuberculosis drug production? An assessment of current capacity and challenges"],"prefix":"10.1186","volume":"13","author":[{"given":"Andre","family":"Gemal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Keravec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Menezes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anete","family":"Trajman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,3,27]]},"reference":[{"key":"5310_CR1","first-page":"100","volume-title":"WHO | Global tuberculosis report 2012","author":"World Health Organization","year":"2012","unstructured":"World Health Organization: WHO | Global tuberculosis report 2012. 2012, Geneva, Switzerland: WHO, 100-"},{"key":"5310_CR2","unstructured":"HIV and TB | Factsheets | CDC HIV\/AIDS. [http:\/\/www.cdc.gov\/hiv\/resources\/factsheets\/hivtb.htm]"},{"key":"5310_CR3","unstructured":"United Nations Millennium Development Goals. [http:\/\/www.un.org\/millenniumgoals\/aids.shtml]"},{"key":"5310_CR4","first-page":"101","volume-title":"The Global Plan to Stop TB 2011\u20132015","author":"WHO, Stop TB Partnership","year":"2011","unstructured":"WHO, Stop TB Partnership: The Global Plan to Stop TB 2011\u20132015. 2011, Geneva, Switzerland: WHO, 101-"},{"key":"5310_CR5","first-page":"119","volume-title":"WHO | Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015","author":"World Health Organization","year":"2011","unstructured":"World Health Organization: WHO | Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. 2011, Geneva, Switzerland: WHO, 119-"},{"key":"5310_CR6","first-page":"180","volume":"57","author":"R Prasad","year":"2010","unstructured":"Prasad R: Multidrug and extensively drug-resistant TB (M\/XDR-TB): problems and solutions. Indian J Tuberc. 2010, 57: 180-191.","journal-title":"Indian J Tuberc"},{"key":"5310_CR7","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.5588\/ijtld.10.0591","volume":"15","author":"J Furin","year":"2011","unstructured":"Furin J, Bayona J, Becerra M, Farmer P, Golubkov A, Hurtado R, Joseph JK, Keshavjee S, Ponomarenko O, Rich M, Shin S: Programmatic management of multidrug-resistant tuberculosis: models from three countries. Int J Tuberc Lung Dis. 2011, 15: 1294-1300. 10.5588\/ijtld.10.0591.","journal-title":"Int J Tuberc Lung Dis"},{"key":"5310_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5588\/ijtld.11.0158","volume":"15","author":"C Lienhardt","year":"2011","unstructured":"Lienhardt C, Cobelens FGJ: Operational research for improved tuberculosis control: the scope, the needs and the way forward. Int J Tuberc Lung Dis. 2011, 15: 6-13. 10.5588\/ijtld.11.0158.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"Suppl 2","key":"5310_CR9","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.1093\/infdis\/jis188","volume":"205","author":"F Cobelens","year":"2012","unstructured":"Cobelens F, van den Hof S, Pai M, Squire SB, Ramsay A, Kimerling ME: Which new diagnostics for tuberculosis, and when?. J Infect Dis. 2012, 205 (Suppl 2): S191-198. 10.1093\/infdis\/jis188.","journal-title":"J Infect Dis"},{"key":"5310_CR10","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1590\/S0102-311X2006001100012","volume":"22","author":"EA de Oliveira","year":"2006","unstructured":"de Oliveira EA, Labra ME, Bermudez J: [Public production of medicines in Brazil: an overview]. Cad Saude Publica. 2006, 22: 2379-2389.","journal-title":"Cad Saude Publica"},{"key":"5310_CR11","volume-title":"Manual de Recomenda\u00e7\u00f5es para o Controle da Tuberculose no Brasil","author":"Brasil. Minist\u00e9rio da Sa\u00fade","year":"2011","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade: Manual de Recomenda\u00e7\u00f5es para o Controle da Tuberculose no Brasil. 2011, 186: http:\/\/portal.saude.gov.br\/portal\/arquivos\/pdf\/manual_de_recomendacoes_tb.pdf,"},{"key":"5310_CR12","first-page":"622","volume":"4","author":"AL Kritski","year":"2000","unstructured":"Kritski AL, Ruffino-Netto A: Health sector reform in Brazil: impact on tuberculosis control. Int J Tuberc Lung Dis. 2000, 4: 622-626.","journal-title":"Int J Tuberc Lung Dis"},{"key":"5310_CR13","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/S0140-6736(11)60054-8","volume":"377","author":"J Paim","year":"2011","unstructured":"Paim J, Travassos C, Almeida C, Bahia L, Macinko J: The Brazilian health system: history, advances, and challenges. Lancet. 2011, 377: 1778-1797. 10.1016\/S0140-6736(11)60054-8.","journal-title":"Lancet"},{"key":"5310_CR14","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1590\/S1806-37132009001000011","volume":"35","author":"MB Conde","year":"2009","unstructured":"Conde MB, Marques AMC, Cardoso NC, Pinheiro VGF, de TR DP, Machado Junior A, Lemos ACM, Netto AR, Durovni B, Sant\u2019Anna CC, Lima D, Capone D, Barreira D, Matos ED, David FC, Marsico G, Afiune JB, Jamal LF, Hirata MH, Rabahi MF, Cailleaux-Cesar M, Palaci M, Morrone N, Guerra RL, Dietze R: III Brazilian Thoracic Association Guidelines on Tuberculosis. Jornal Brasileiro de Pneumologia. 2009, 35: 1018-1048.","journal-title":"Jornal Brasileiro de Pneumologia"},{"key":"5310_CR15","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. [http:\/\/portal.anvisa.gov.br\/wps\/portal\/anvisa\/home]"},{"key":"5310_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1590\/S0102-311X2002000100022","volume":"18","author":"J Galvao","year":"2002","unstructured":"Galvao J: Brazilian policy for the distribution and production of antiretroviral drugs: a privilege or a right?. Cad Saude Publica. 2002, 18: 213-219. 10.1590\/S0102-311X2002000100022.","journal-title":"Cad Saude Publica"},{"key":"5310_CR17","unstructured":"Fiocruz \/ Farmanguinhos | Lista de produtos. [http:\/\/www2.far.fiocruz.br\/farmanguinhos\/]"},{"key":"5310_CR18","unstructured":"Fiocruz \/ Farmanguinhos | Farmanguinhos combate a tuberculose. [http:\/\/www2.far.fiocruz.br\/farmanguinhos\/]"},{"key":"5310_CR19","unstructured":"WHO | Prequalification of medicines by WHO. [http:\/\/apps.who.int\/prequal\/query\/ProductRegistry.aspx?list=tb]"},{"key":"5310_CR20","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/S0140-6736(02)09096-7","volume":"359","author":"P Trouiller","year":"2002","unstructured":"Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N: Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet. 2002, 359: 2188-2194. 10.1016\/S0140-6736(02)09096-7.","journal-title":"Lancet"},{"key":"5310_CR21","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1590\/S0034-89102009005000041","volume":"43","author":"FS Vieira","year":"2009","unstructured":"Vieira FS: Ministry of Health\u2019s spending on drugs: program trends from 2002 to 2007. Revista de Sa\u00fade P\u00fablica. 2009, 43: 674-681.","journal-title":"Revista de Sa\u00fade P\u00fablica"},{"key":"5310_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1590\/S1020-49892010000200010","volume":"27","author":"FS Vieira","year":"2010","unstructured":"Vieira FS: Pharmaceutical assistance in the Brazilian public health care system. Revista Panamericana de Salud P\u00fablica. 2010, 27: 149-156. 10.1590\/S1020-49892010000200010.","journal-title":"Revista Panamericana de Salud P\u00fablica"},{"key":"5310_CR23","volume-title":"Fatal Imbalance The Crisis in Research and Development for Drugs for Neglected Diseases","author":"M\u00e9decins Sans Fronti\u00e8res Access to Essential Medicines Campaign, The Drugs for Neglected Diseases Working Group","year":"2011","unstructured":"M\u00e9decins Sans Fronti\u00e8res Access to Essential Medicines Campaign, The Drugs for Neglected Diseases Working Group: Fatal Imbalance The Crisis in Research and Development for Drugs for Neglected Diseases. 2011, Brussels, Belgium: M\u00e9decins Sans Fronti\u00e8res Access to Essential Medicines Campaign and the Drugs for Neglected Diseases Working Group"},{"key":"5310_CR24","volume-title":"Multinational Drug Companies: Issues in Drug Discovery and Development. 1989th edition","author":"B Spilker","year":"1989","unstructured":"Spilker B: Multinational Drug Companies: Issues in Drug Discovery and Development. 1989th edition. 1989, New York: Raven Pr"},{"key":"5310_CR25","first-page":"14","volume-title":"Report of TB Drug Manufacturers Meeting Aug 29\u201330 2011, New Dehli","author":"Stop TB Partnership","year":"2011","unstructured":"Stop TB Partnership: Report of TB Drug Manufacturers Meeting Aug 29\u201330 2011, New Dehli. 2011, New Dehli, India, 14-"},{"key":"5310_CR26","unstructured":"World Health Organization: Prequalification of medicines by WHO. Fact sheet # 278. Available at http:\/\/www.who.int\/mediacentre\/factsheets\/fs278\/en\/"},{"key":"5310_CR27","volume-title":"Legisla\u00e7\u00e3o Federal do Brasil. Lei 12.349\/2010","author":"Presid\u00eancia da Rep\u00fablica do Brasil","year":"2010","unstructured":"Presid\u00eancia da Rep\u00fablica do Brasil: Legisla\u00e7\u00e3o Federal do Brasil. Lei 12.349\/2010. 2010"},{"key":"5310_CR28","first-page":"258","volume-title":"WHO | Global tuberculosis control 2011","author":"World Health Organization","year":"2011","unstructured":"World Health Organization: WHO | Global tuberculosis control 2011. 2011, Geneva, Switzerland: World Health Organization, 258-www.who.int\/tb\/publications\/global_report\/,"},{"key":"5310_CR29","unstructured":"Inmetro - Instituto Nacional de Metrologia, Qualidade e Tecnologia. [http:\/\/www.inmetro.gov.br\/]"},{"key":"5310_CR30","volume-title":"Farmacop\u00e9ia Brasileira 5a Edi\u00e7\u00e3o - 2010 - Anvisa","author":"Minist\u00e9rio da Sa\u00fade. Ag\u00eancia Nacional de Vigil\u00e2ncia em Sa\u00fade","year":"2010","unstructured":"Minist\u00e9rio da Sa\u00fade. Ag\u00eancia Nacional de Vigil\u00e2ncia em Sa\u00fade: Farmacop\u00e9ia Brasileira 5a Edi\u00e7\u00e3o - 2010 - Anvisa. 2010, Brasilia, DF: Editora Fiocruz, 5","edition":"5"},{"key":"5310_CR31","first-page":"80","volume-title":"Regional Plan for Tuberculosis Control, 2006\u20132015","author":"Pan American Health Organization","year":"2006","unstructured":"Pan American Health Organization: Regional Plan for Tuberculosis Control, 2006\u20132015. 2006, Washington DC: Pan American Health Organization, 80-"},{"key":"5310_CR32","volume-title":"Technological Innovations in Brazil. Performance, Policies and potential","author":"RU Sennes","year":"2012","unstructured":"Sennes RU, Brito Filho A: Technological Innovations in Brazil. Performance, Policies and potential. 2012, Cultura Acad\u00eamica: S\u00e3o Paulo"},{"issue":"Suppl 1","key":"5310_CR33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1590\/S0034-89102007000800003","volume":"41","author":"AL Kritski","year":"2007","unstructured":"Kritski AL, Villa TS, Trajman A, Lapa E, Silva JR, Medronho RA, Ruffino-Netto A: [Two decades of research on tuberculosis in Brazil: state of the art of scientific publications]. Rev Saude Publica. 2007, 41 (Suppl 1): 9-14.","journal-title":"Rev Saude Publica"},{"key":"5310_CR34","first-page":"1","volume-title":"Origens e Trajet\u00f3rias da Ind\u00fastria Farmac\u00eautica no Brasil","author":"FEBRAFARMA","year":"2007","unstructured":"FEBRAFARMA: Origens e Trajet\u00f3rias da Ind\u00fastria Farmac\u00eautica no Brasil. 2007, S\u00e3o Paulo: Narrativa 1, 1-1","edition":"1"},{"key":"5310_CR35","first-page":"34","volume-title":"Drugs for Neglected Diseases Innitiatives Annual Report 2011","author":"DNDi","year":"2011","unstructured":"DNDi: Drugs for Neglected Diseases Innitiatives Annual Report 2011. 2011, 34-"},{"key":"5310_CR36","unstructured":"European Comission: Aid Effectiveness Agenda: Benefits of a European Approach. Available at http:\/\/www.fride.org\/event\/246\/the-aid-effectiveness-agenda-in-european-and-south-south-cooperation"},{"key":"5310_CR37","unstructured":"Rede - TB. [http:\/\/www.redetb.org\/]"},{"key":"5310_CR38","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.5588\/ijtld.12.0277","volume":"16","author":"JH Grosset","year":"2012","unstructured":"Grosset JH, Singer TG, Bishai WR: New drugs for the treatment of tuberculosis: hope and reality [State of the Art Series. New tools. Number 2 in the series]. Int J Tuberc Lung D. 2012, 16: 1005-1014. 10.5588\/ijtld.12.0277.","journal-title":"Int J Tuberc Lung D"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2458-13-279.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2458-13-279\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2458-13-279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2458-13-279.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T23:50:02Z","timestamp":1630540202000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/1471-2458-13-279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,27]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["5310"],"URL":"https:\/\/doi.org\/10.1186\/1471-2458-13-279","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,27]]},"assertion":[{"value":"3 November 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"279"}}